Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

Nature volume 542, pages 362–366 (2017)Cite this article

Subjects

Abstract

Malignant neoplasms evolve in response to changes in oncogenic signalling1. Cancer cell plasticity in response to evolutionary pressures is fundamental to tumour progression and the development of therapeutic resistance2,3. Here we determine the molecular and cellular mechanisms of cancer cell plasticity in a conditional oncogenic Kras mouse model of pancreatic ductal adenocarcinoma (PDAC), a malignancy that displays considerable phenotypic diversity and morphological heterogeneity. In this model, stochastic extinction of oncogenic Kras signalling and emergence of Kras-independent escaper populations (cells that acquire oncogenic properties) are associated with de-differentiation and aggressive biological behaviour. Transcriptomic and functional analyses of Kras-independent escapers reveal the presence of Smarcb1–Myc-network-driven mesenchymal reprogramming and independence from MAPK signalling. A somatic mosaic model of PDAC, which allows time-restricted perturbation of cell fate, shows that depletion of Smarcb1 activates the Myc network, driving an anabolic switch that increases protein metabolism and adaptive activation of endoplasmic-reticulum-stress-induced survival pathways. Increased protein turnover renders mesenchymal sub-populations highly susceptible to pharmacological and genetic perturbation of the cellular proteostatic machinery and the IRE1-α–MKK4 arm of the endoplasmic-reticulum-stress-response pathway. Specifically, combination regimens that impair the unfolded protein responses block the emergence of aggressive mesenchymal subpopulations in mouse and patient-derived PDAC models. These molecular and biological insights inform a potential therapeutic strategy for targeting aggressive mesenchymal features of PDAC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Identification and functional characterization of mesenchymal sub-populations in pancreatic cancer.
Figure 2: Smarcb1 restrains the expansion of aggressive mesenchymal clones in PDAC.
Figure 3: Genetic perturbation of ER-stress response pathway is lethal in a Smarcb1-deficient context.
Figure 4: Pharmacological perturbation of proteostasis induces tumour regression in cooperation with gemcitabine in pre-clinical models of pancreatic cancer.

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)

    Article  CAS  Google Scholar 

  2. Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21–45 (2016)

    Article  CAS  Google Scholar 

  3. Pisco, A. O. & Huang, S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me’. Br. J. Cancer 112, 1725–1732 (2015)

    Article  CAS  Google Scholar 

  4. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012)

    Article  CAS  Google Scholar 

  5. Kopp, J. L. et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22, 737–750 (2012)

    Article  CAS  Google Scholar 

  6. Morris, J. P., IV, Cano, D. A., Sekine, S., Wang, S. C. & Hebrok, M. β-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508–520 (2010)

    Article  CAS  Google Scholar 

  7. Lee, K. E. & Bar-Sagi, D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 18, 448–458 (2010)

    Article  CAS  Google Scholar 

  8. Reichert, M. et al. Isolation, culture and genetic manipulation of mouse pancreatic ductal cells. Nat. Protocols 8, 1354–1365 (2013)

    Article  Google Scholar 

  9. Isakoff, M. S. et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc. Natl Acad. Sci. USA 102, 17745–17750 (2005)

    Article  ADS  CAS  Google Scholar 

  10. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112 (2009)

    Article  ADS  CAS  Google Scholar 

  11. Creighton, C. J. et al. Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res. 66, 3903–3911 (2006)

    Article  CAS  Google Scholar 

  12. Ma, Y., Croxton, R., Moorer, R. L., Jr & Cress, W. D. Identification of novel E2F1-regulated genes by microarray. Arch. Biochem. Biophys. 399, 212–224 (2002)

    Article  CAS  Google Scholar 

  13. Chiou, S. H. et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev. 29, 1576–1585 (2015)

    Article  CAS  Google Scholar 

  14. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011)

    Article  CAS  Google Scholar 

  15. Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat. Med. 22, 278–287 (2016)

    Article  CAS  Google Scholar 

  16. Signer, R. A., Magee, J. A., Salic, A. & Morrison, S. J. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature 509, 49–54 (2014)

    Article  ADS  CAS  Google Scholar 

  17. Hart, L. S. et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Invest. 122, 4621–4634 (2012)

    Article  CAS  Google Scholar 

  18. Lin, J. H. et al. IRE1 signaling affects cell fate during the unfolded protein response. Science 318, 944–949 (2007)

    Article  ADS  CAS  Google Scholar 

  19. Urano, F. et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664–666 (2000)

    Article  ADS  CAS  Google Scholar 

  20. Chen, Y. & Brandizzi, F. IRE1: ER stress sensor and cell fate executor. Trends Cell Biol. 23, 547–555 (2013)

    Article  CAS  Google Scholar 

  21. Chien, W. et al. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget 5, 4881–4894 (2014)

    PubMed  PubMed Central  Google Scholar 

  22. Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318–1325 (2015)

    Article  CAS  Google Scholar 

  23. Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315–5319 (2013)

    Article  CAS  Google Scholar 

  24. Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311–316 (2015)

    Article  CAS  Google Scholar 

  25. Carugo, A. et al. In vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer. Cell Reports 16, 133–147 (2016)

    Article  CAS  Google Scholar 

  26. Singh, A. et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489–500 (2009)

    Article  CAS  Google Scholar 

  27. Agaimy, A. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. Adv. Anat. Pathol. 21, 394–410 (2014)

    Article  CAS  Google Scholar 

  28. Agaimy, A., Rau, T. T., Hartmann, A. & Stoehr, R. SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. Am. J. Surg. Pathol. 38, 910–920 (2014)

    Article  Google Scholar 

  29. Agaimy, A. et al. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. Mod. Pathol. 28, 248–260 (2015)

    Article  CAS  Google Scholar 

  30. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007)

    Article  CAS  Google Scholar 

  31. Young, N. P. & Jacks, T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107, 10184–10189 (2010)

    Article  ADS  CAS  Google Scholar 

  32. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001)

    Article  CAS  Google Scholar 

  33. Cheung, A. F., Dupage, M. J., Dong, H. K., Chen, J. & Jacks, T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res. 68, 9459–9468 (2008)

    Article  CAS  Google Scholar 

  34. Lee, C. L. et al. Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice. Dis. Model. Mech. 5, 397–402 (2012)

    Article  CAS  Google Scholar 

  35. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605 (2007)

    Article  CAS  Google Scholar 

  36. Roberts, C. W., Leroux, M. M., Fleming, M. D. & Orkin, S. H. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2, 415–425 (2002)

    Article  CAS  Google Scholar 

  37. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003)

    Article  CAS  Google Scholar 

  38. Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994–1004 (2000)

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134 (2002)

    Article  CAS  Google Scholar 

  40. Lao, Z., Raju, G. P., Bai, C. B. & Joyner, A. L. MASTR: a technique for mosaic mutant analysis with spatial and temporal control of recombination using conditional floxed alleles in mice. Cell Rep. 2, 386–396 (2012)

    Article  CAS  Google Scholar 

  41. Snippert, H. J. et al. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134–144 (2010)

    Article  CAS  Google Scholar 

  42. Kissler, S. et al. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat. Genet. 38, 479–483 (2006)

    Article  CAS  Google Scholar 

  43. Ventura, A. et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl Acad. Sci. USA 101, 10380–10385 (2004)

    Article  ADS  CAS  Google Scholar 

  44. Koo, B. K. et al. Controlled gene expression in primary Lgr5 organoid cultures. Nat. Methods 9, 81–83 (2011)

    Article  Google Scholar 

  45. Campeau, E. et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4, e6529 (2009)

    Article  ADS  Google Scholar 

  46. Young, N. P., Crowley, D. & Jacks, T. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 71, 4040–4047 (2011)

    Article  CAS  Google Scholar 

  47. Genovese, G. et al. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov. 2, 736–749 (2012)

    Article  CAS  Google Scholar 

  48. Winslow, M. M. et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473, 101–104 (2011)

    Article  ADS  CAS  Google Scholar 

  49. Beerling, E. et al. Plasticity between epithelial and mesenchymal states unlinks emt from metastasis-enhancing stem cell capacity. Cell Reports 14, 2281–2288 (2016)

    Article  CAS  Google Scholar 

  50. Kim, M. P. et al. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann. Surg. Oncol. 19 (Suppl. 3), S395–S403 (2012)

    Article  Google Scholar 

  51. Kim, M. P. et al. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat. Protocols 4, 1670–1680 (2009)

    Article  CAS  Google Scholar 

  52. Viale, A. et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014)

    Article  ADS  CAS  Google Scholar 

  53. Agbunag, C., Lee, K. E., Buontempo, S. & Bar-Sagi, D. Pancreatic duct epithelial cell isolation and cultivation in two-dimensional and three-dimensional culture systems. Methods Enzymol. 407, 703–710 (2006)

    Article  CAS  Google Scholar 

  54. Rudalska, R. et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138–1146 (2014)

    Article  CAS  Google Scholar 

  55. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008)

    Article  ADS  CAS  Google Scholar 

  56. Bonnefoix, T., Bonnefoix, P., Verdiel, P. & Sotto, J. J. Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J. Immunol. Methods 194, 113–119 (1996)

    Article  CAS  Google Scholar 

  57. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)

    Article  ADS  CAS  Google Scholar 

  58. Ashburner, M. et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank D. Spring, A. Futreal, P. Jones, J. Marszalek, I. Watson, Y. Lissanu Deribe, K. Rai and J. Horner for discussions and suggestions. We thank A. Petrocchi, E. Di Francesco, E. Paul and T. Tieu for providing reagents. We wish to thank the members of the Chin, DePinho and Draetta labs for discussions and reagents; K. Dunner, Jr. and the High Resolution Electron Microscopy Facility at MDACC for TEM (Cancer Center Core Grant CA16672); M. Keith, C. Kingsley, the MDACC Small Animals Imaging Facility, the UTMDACC Microarray Core Facility, the MDACC Department of Veterinary Medicine and the UTMDACC Flow Facility. L.C. was supported by the CPRIT R1204 and NIH 5 U01 CA141508. G.F.D. was supported by the AACR 14-90-25 and by the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Grant. A.C. was supported by the FIRC (Fondazione Italiana per la Ricerca sul Cancro) Fellowship. G.G. was supported by the FIRC fellowship.

Author information

Author notes

  1. Alessandro Carugo, Timothy P. Heffernan & Lynda Chin

    Present address: †Present addresses: C4 Therapeutics, Cambridge, Massachusetts 02142, USA (T.P.H.); Institute for Health Transformation, The University of Texas System, Austin, Texas 78701, USA (L.C.),

  2. James Tepper, Frederick Scott Robinson and Liren Li: These authors contributed equally to this work.

  3. gdraetta@mdanderson.org

Authors and Affiliations

  1. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA

    Giannicola Genovese, Alessandro Carugo, James Tepper, Frederick Scott Robinson, Liren Li, Maria Svelto, Luigi Nezi, Denise Corti, Rosalba Minelli, Piergiorgio Pettazzoni, Tony Gutschner, Chia-Chin Wu, Sahil Seth, Kadir Caner Akdemir, Samirkumar Amin, Koichi Takahashi, Andrea Viale, Giulio F. Draetta & Lynda Chin

  2. Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Alessandro Carugo, Frederick Scott Robinson, Elisabetta Leo, Virginia Giuliani, Jill Garvey, Jianhua Zhang, Timothy P. Heffernan, Giulio F. Draetta & Lynda Chin

  3. European Institute of Oncology, Milano, 20141, Italy

    Alessandro Carugo

  4. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, 510060, China,

    Liren Li

  5. Istituto di Patologia Generale, Universitá Cattolica del Sacro Cuore, Rome 00168, Italy,

    Maria Svelto & Alessandro Sgambato

  6. Graduate program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, Texas 77030, USA,

    Samirkumar Amin

  7. Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland 21287, USA,

    Marco Dal Molin, Michael G. Goggins & Laura D. Wood

  8. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Haoqiang Ying

  9. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Lawrence N. Kwong

  10. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Simona Colla & Koichi Takahashi

  11. Office of Technology Commercialization, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Papia Ghosh

  12. Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

    Florian Muller

  13. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Prasenjit Dey, Shan Jiang & Ronald A. DePinho

  14. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

    Chang-Gong Liu

  15. ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Carlo Toniatti

  16. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

    Jason B. Fleming

  17. Department of Pathology, Friedrich Alexander University Erlangen-Nuremberg, University Hospital, Erlangen 91054, Germany

    Abbas Agaimy

  18. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Anirban Maitra & Huamin Wang

  19. Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA,

    Anirban Maitra

  20. Comprehensive Cancer Center and Department of Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee 77027, USA,

    Charles W. M. Roberts

Authors
  1. Giannicola Genovese
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Carugo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Tepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frederick Scott Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liren Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Svelto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luigi Nezi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Denise Corti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rosalba Minelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Piergiorgio Pettazzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tony Gutschner
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chia-Chin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sahil Seth
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kadir Caner Akdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Elisabetta Leo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Samirkumar Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marco Dal Molin
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Haoqiang Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Lawrence N. Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Simona Colla
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Koichi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Papia Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Virginia Giuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Florian Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Prasenjit Dey
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Shan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Jill Garvey
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Chang-Gong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Jianhua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Timothy P. Heffernan
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Carlo Toniatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Jason B. Fleming
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Michael G. Goggins
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Laura D. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Alessandro Sgambato
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Abbas Agaimy
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Anirban Maitra
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Charles W. M. Roberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. Huamin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. Andrea Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. Ronald A. DePinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  42. Giulio F. Draetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  43. Lynda Chin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

G.G. designed the study with input from L.C., G.F.D., P.G., A.C., C.W.M.R., A.V., T.G., R.A.D. and other authors. In vitro experiments were performed by G.G., M.S., F.S.R., J.T., D.C. and A.C. Viral vectors were designed by G.G. and M.S. with input from S.C. and A.C. In vivo studies were performed by G.G., L.L., A.C., J.T. and P.P. with help from T.G., K.T. and F.M. The mouse colonies were maintained and genotyped by F.S.R., G.G. and A.C. with help from S.J. and J.G. Immunohistochemistry and immunofluorescence were performed by G.G., J.T., L.N. and A.V. FACS studies were performed by A.V. and E.L. FACS data analysis was performed by A.V. and E.L. Drug studies were performed by G.G. and J.T. with the help of P.P., T.P.H., C.T. and V.G. Bioinformatic analysis was performed by S.S., K.C.A., S.A. and J.Z. with input from G.G., L.N.K. and A.C. Human tissues were obtained by H.W., J.B.F., A.S., A.M., M.D.M., M.G.G., L.D.W. and A.A. Slides were scored by H.W. and G.G. G.G., A.C., G.F.D., P.G. and L.C. reviewed statistical analysis and proof-read the final version of the manuscript.

Corresponding authors

Correspondence to Giannicola Genovese or Giulio F. Draetta.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

Reviewer Information Nature thanks Z. Ronai and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Extended data figures and tables

Extended Data Figure 1 Molecular characterization of escaper clones.

a, Schematic representation of the experimental workflow. Pancreatic epithelial cells (PEC) were isolated from KrasG12D-mutant pancreata and cultured ex vivo under the selective pressure of oncogenic stress. Serial passaging resulted in two different outputs: senescence or the establishment of escaper clones. b, Representative panels of senescence-associated β-galactosidase staining in pancreatic epithelial cells at passages P4 and P7. c, Far left, representative sections of escaper-derived tumours, haematoxylin and eosin stained, displaying mesenchymal-like or epithelial morphology. Insets show the morphology of the original clone in 2D culture. Mid-left to far right, immunohistochemical staining for the EMT markers vimentin, nestin and CDH1, respectively, in tumours derived from EPI and MS-L transplants. d, Assessment of 3D clonogenic growth in vitro (n = 4 per group). Data are mean ± s.d. of technical replicates (one representative experiment of three). MS-L cells show an enhanced ability to form spheres in methylcellulose-based semi-solid culture medium. e, TIC frequency of EPI and MS-L cells as assessed by limiting dilution experiments in immunocompromised (NCr Nude) mice. Two individual clones per group were tested (EPI#1: n = 19, EPI#2: n = 23, MS-L#1: n = 20, MS-L#2: n = 20). TIC was calculated using the L-Calc software. Data are the mean proportion of TICs ± s.e.m. ***P < 0.001, ****P < 0.0001 by two-tailed chi-squared test. f, Representative pictures of livers from mice orthotopically injected with EPI or MS-L cells. g, Volcano plot showing the number of differentially expressed genes between EPI and MS-L escapers. h, GSEA enrichment analysis plots for gene sets upregulated in EPI (top) and MS-L (bottom) escaper cells. EPI escapers display enrichment for Kras- and Mek-driven transcriptomic gene signatures, MS-L escapers are characterized by the perturbation of transcriptomic targets of the SWI/SNF chromatin remodelling factor Smarcb1 and dysregulation of genetic programs involved in progression through the cell cycle. i, Immunohistochemical profile of EPI and MS-L escapers and validation of the transcriptomic analysis. EPI escapers exhibit robust MAPK signalling, as assessed with antibodies specific for phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) and phospho-MEK1/2 (Ser221); by contrast, MS-L escapers display a lack of MAPK signalling activation, downregulation of SMARCB1 levels and an increase in the proliferative index assessed by Ki67 staining. Scale bars, 100 μm (c, i).

Source data

Extended Data Figure 2 Isolation and functional characterization of epithelial and mesenchymal clones from primary tumours in a conditional reporter GEMM of PDAC.

a, Schematic model of the GEMM. KrasG12DLSL/+-Tp53LoxP/LoxP-Pdx1-Cre (KPC∆/∆) mice were crossed with a strain expressing a lineage-tracing fluorescent reporter (R26mTmG) and a strain expressing a Cdh1Cfp reporter, in which CFP (cyan fluorescent protein) is expressed as a fusion protein with endogenous E-cadherin to generate the KPC∆/∆-R26mTmG/+-Cdh1Cfp/+ dual-reporter model of PDAC. This system allows the isolation of GFP-positive malignant cells and the separation of CFPhigh (epithelial) from CFPlow (mesenchymal) sub-populations. b, FACS experiment showing the distribution of CFPhigh and CFPlow sub-populations in both the GFP+ (tumour cells) compartment and the TdTomato+ (stromal) compartment. The reporter shows an absence of CFP+ cells in the stromal (TdTomato+) compartment and a spectrum of sub-populations in the tumour (GFP+) compartment. c, Western blot analysis of the expression levels of SMARCB1 in the GFP+CFPhigh and GFP+CFPlow sub-populations. Vinculin was used as loading control. d, Representative sections showing the levels of SMARCB1, CDH1 and phospho-ERK1/2 in orthotopic transplants of malignant sub-populations, isolated as described above. MS-L-derived transplants were used as controls. e, In vivo characterization of the PDAC sub-populations in the KPC∆/∆-R26mTmG/+ model of PDAC. Immunofluorescence staining for GFP, SMARCB1, phospho-ERK1/2 and nestin in PDAC originated in the KPC∆/∆-R26mTmG/+ background strain. Low levels of SMARCB1 and phospho-ERK1/2 and high levels of nestin are a hallmark of the sub-population of invasive GFP+ cells. Scale bars, 100 μm (d, e, bottom nine panels), 20 μm (e, top four panels). For gel source data, see Supplementary Figures.

Extended Data Figure 3 Functional characterization of a Kras/Smarcb1 axis in the maintenance of epithelial identity and in mesenchymal reprograming.

a, RNAi-mediated knockdown of Kras in EPI-derived orthotopic transplants achieved with a lentiviral-based technology results in aggressive tumours that faithfully recapitulate the biological behaviour of MS-L transplants. Kaplan–Meier survival analysis of NCr Nude mice transplanted with MS-L escapers and EPI escapers transduced with either shCtrl or shKras constructs (n = 5 per group). Tumours emerging in the Kras-depleted group display longer latencies; however, once established, they faithfully recapitulate the behaviour of MS-L tumours in secondary transplants. b, TIC frequencies for shCtrl and shKras reprogrammed EPI escapers assessed by limiting dilution transplantation studies in immunocompromised (NCr Nude) mice (EPI and shCtrl: n = 27; EPI and shKras: n = 25) and calculated using the L-Calc software. Data are the mean proportion of TICs ± s.e.m. c, Transcript levels for Kras and Smarcb1 in EPI cells transduced with shCtrl or shKras constructs assessed by qPCR 96 h after transduction. RNAi-mediated depletion of Kras results in an acute drop in the levels of Smarcb1 (n = 3). Data are mean ± s.d. of technical replicates (one representative experiment out of three). d, Immunohistochemical quantification of the levels of phospho- Erk1/2 and SMARCB1 in tumours generated by EPI cells transduced with shCtrl or shKras constructs. Depletion of Kras results in tumours characterized by lack of activation of the MAPK signalling and a profound drop in the levels of nuclear SMARCB1. e, Western blot analysis of the expression of SMARCB1, E-cadherin (CDH1) and nestin in EPI, MS-L clones and EPI clones re-programmed with lentiviral-based shRNAs against Smarcb1 (sh1 and sh855). Vinculin was used as loading control. f, Liver-seeding assay for the quantification of metastatic potential. Liver weight of NCr Nude mice that receievd an intra-splenic injection of EPI cells infected with a lentiviral vector harbouring a control shRNA or a shRNA against Smarcb1 (sh855). MS-L cells were used as positive controls (n = 5 per group). Data are mean ± s.d. of biological replicates. RNAi-mediated ablation of Smarcb1 results in higher metastatic burden. g, Kaplan–Meier analysis of survival of NCr Nude mice orthotopically injected with EPI cells that were infected with a lentiviral vector harbouring a control shRNA or a shRNA against Smarcb1 (sh855). MS-L cells were used as positive control (n = 5 per group). h, Ablation of Smarcb1 in the pancreatic epithelia potently co-operates with mutant KrasG12D in driving aggressive tumours with full penetrance and a median latency of 5–7 weeks. Kaplan–Meier survival analysis. Pdx1-Cre-KrasG12DLSL/+-Smarcb1LoxP/LoxP (KSC∆/∆), n = 29; Pdx1-Cre-KrasG12DLSL/+-Tp53LoxP/LoxP (KPC∆/∆), n = 42; Pdx1-Cre-Smarcb1LoxP/LoxP (CS∆/∆), n = 21; Pdx1-Cre-KrasG12DLSL/+ (KC), n = 36; Pdx1-Cre-KrasG12DLSL/+-Tp53LoxP/LoxP-Smarcb1LoxP/LoxP (KPSC∆/∆), n = 16). KSC∆/∆ versus KC, P < 0.0001; KPSC∆/∆ versus KSC∆/∆, P < 0.0001; KPSC∆/∆ versus KPC∆/∆, P < 0.0001 by Mantel–Cox log-rank test. i, TIC frequency in Smarcb1-ablated tumours (KSC∆/∆, KPSC∆/∆) compared to the Smarcb1-proficient background (KPC∆/∆), as assessed by limiting-dilution transplantation experiments in NCr Nude mice (KPC∆/∆, n = 20; KSC∆/∆, n = 20; KPSC∆/∆, n = 18) and calculated using the L-Calc software. Data shown as the mean proportion of TICs ± s.e.m. j, Liver weight of NCr Nude mice receiving intra-splenic transplants of low-passage tumour cells isolated from KPC∆/∆-R26Cag-LSL-Luc/+, KSC∆/∆-R26Cag-LSL-Luc/+ and KPSC∆/∆-R26Cag-LSL-Luc/+ tumours (n = 10 per group). Data are mean ± s.d. of biological replicates. k, Top, representative luciferase images for liver-seeding assays described in j. The intensity of the signal is proportional to the metastatic burden. Colour scale bar is a reference for the intensity of the luminescence signal. Bottom panels show representative images of low-passages tumour cells in 2D. Original image magnification, ×20. Cells lacking Smarcb1 are loosely cohesive and characterized by a prominent mesenchymal morphology and a propensity for growth in suspension. l, Immunohistochemical profile of Smarcb1-deficient tumours (KSC∆/∆) compared to Smarcb1-proficient lesions (KC, KPC∆/∆) and wild-type (Wt) pancreata. Samples were stained for the EMT markers vimentin, nestin and CDH1. Normal wild-type pancreata, pre-neoplastic lesions from the KC background and PDAC from the KPC∆/∆ background were used as controls. At 8–10 weeks old, mice were killed and pancreata/pancreatic lesions were collected. Hallmarks of Smarcb1-ablated tumours are the complete loss of CDH1 and the robust expression of the mesenchymal markers vimentin and nestin when compared to neoplastic and pre-malignant lesions originating in the Smarcb1-proficient backgrounds (KC and KPC∆/∆). m, Histopathological grade distribution in conditional GEMMs of PDAC (KPC∆/∆, n = 28; KSC∆/∆, n = 29; KPSC∆/∆, n = 15). n, Spherogenic potential of low-passage spheroids obtained from tumours arising in the KPC∆/∆, KSC∆/∆ and KPSC∆/∆ genetic background (n = 3 per group). Data are mean ± s.d. of technical replicates (one representative experiment out of three). o, Representative gross image of a KSC∆/∆ mouse at necropsy. p, FACS analysis for the putative stem-cell marker aldefluor in freshly isolated tumour cells from the KC, KPC∆/∆, KSC∆/∆ and KPSC∆/∆ backgrounds. Diethylaminobenzaldehyde-treated cells were used as negative control. Smarcb1-deficient cells display a robust increase in the relative number of aldefluor positive cells. For gel source data see Supplementary Figures. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, by Mantel–Cox log-rank test (a, g), two-tailed chi-squared test (b, i), unpaired two-tailed t-test (f, j) or two-tailed Fisher’s exact test (m). Scale bars, 100 μm (d, l).

Source data

Extended Data Figure 4 Smarcb1 restrains the expansion of mesenchymal clones in PDAC.

a, Schematic showing the lentiviral construct for Flpo-mediated tissue-specific, time-restricted gene inactivation in vivo (pLSM5). High-titre-purified lentiviral particles (2–5 × 108 IU) were introduced surgically into the tail of the pancreas. At 7 days after surgery, mice were treated with caerulein to induce inflammation, proliferation and the expression of genes under the Krt19 promoter in the acinar compartment. The tissue specificity is provided by the human Krt19 promoter driving the expression of the Cre recombinase resulting in the activation of the latent mutant KrasG12DLSL/+, the inactivation of the conditional Tp53LoxP allele and the activation of the R26CAG-LSL-Luc reporter. The time-restricted activation of the shRNA is mediated by the ubiquitous R26Cag-FlpoERT2 inducible, codon-optimized Flpo recombinase upon tamoxifen treatment and removal of the Krt19-Cre stopper cassette, which is flanked by TATA-Frt sites. b, Representative panels showing the gross appearance of pancreata of KP∆/∆-R26mTmG/+ mice orthotopically injected with 108 viral particles, treated with caerulein 7 days after surgery and killed at the 3 weeks (left) or 3 months (right). Arrow indicates mosaic activation of the GFP reporter at 3 weeks. Arrowhead indicates GFP+ tumour nodules at 3 months. TdT, TdTomato. c, Kaplan–Meier analysis of tumour incidence in KP∆/∆-R26mTmG/+ mice orthotopically injected with 108 particles of the pLSM5-K19-Cre vector and assigned to caerulein and vehicle treatment. Caerulein treatment resulted in increased tumour incidence and decreased latency when compared to vehicle control (n = 18 per group). d, Representative luciferase images (left) and pathological characterization (right) of tumours generated with lentiviral-mosaic-somatic technology (R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-1 or R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855). Orthotopic tumours harbouring latent Flpo/Frt-dependent, tamoxifen-inducible shRNAs against Smarcb1 were generated into a Kras-mutant, Tp53-deficient background (KP∆/∆). Mice were monitored weekly for tumour growth by bioluminescence imaging and lesions were characterized by immunophenotypic analysis for pancreatic lineage-differentiation markers before functional studies. e, Expression levels of SMARCB1 and nestin in short-term cultures established from tumours generated in R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1 mice assessed by western blot. Protein lysates were collected 96 h after 4-OHT (4-hydroxytamoxifen) treatment. Vinculin was used as loading control. f, Representative images of liver metastasis stained for haematoxylin and eosin from tamoxifen- and vehicle-treated R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 mice. Tamoxifen-driven acute ablation of Smarcb1 in vivo results in poorly differentiated, invasive lesions. g, Spherogenic potential of low-passage spheroids obtained from R26Cag-FlpoERT2/Cag-LSL-Luc- KP∆/∆-pLSM5-shSmarcb1-1 and R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 tumours upon treatment with 4-hydroxytamoxifen or vehicle control (n = 3 per group). Data are mean ± s.d. of technical replicates (one representative experiment out of three). The acute ablation of Smarcb1 results in a robust increase of the clonogenic potential in the KP∆/∆ background. h, TIC frequency of KP∆/∆-R26Cag-FlpoERT2/Cag-LSL-Luc-pLSM5-shSmarcb1-1 and R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 tumours upon treatment with vehicle or tamoxifen assessed by limiting-dilution experiments in immunocompromised (NCr Nude) mice (sh1 and vehicle, n = 25; sh1 and tamoxifen, n = 20; sh855 and vehicle, n = 19; sh855 and tamoxifen, n = 19) and calculated using the L-Calc software. Data are mean proportion of TIC ± s.e.m. i, j, Metastatic burden assesses by counting the number of superficial liver, peritoneal and lung metastases in NCr Nude mice transplanted orthotopically with R26Cag-FlpoERT2/Cag-LSL-Luc- KP∆/∆-pLSM5-shSmarcb1-1 or R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 tumours assigned to vehicle or tamoxifen treatment. Acute ablation of Smarcb1 resulted in a higher metastatic burden (n = 7 per group). Data are mean ± s.d. of biological replicates. k, Kaplan–Meier survival analysis of NCr Nude mice orthotopically transplanted with R26Cag-FlpoERT2/Cag-LSL-Luc- KP∆/∆-pLSM5-shSmarcb1-1 or R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 tumours (n = 7 per group). Tamoxifen treatment was started 5 days after surgery. Acute ablation of Smarcb1 resulted in more aggressive tumours and a significantly shorter overall survival. l, Representative ex-vivo bioluminescence images in NCr Nude mice orthotopically transplanted with R26Cag-FlpoERT2/Cag-LSL-Luc-KP∆/∆-pLSM5-shSmarcb1-855 tumours and assigned to vehicle or tamoxifen treatment. Arrows indicate metastatic liver disease. m, Schematic showing the lentiviral construct for Cre-mediated, tissue-specific, time-restricted restoration of a gene of interest in vivo (pLSM2). High-titre-purified lentiviral particles (2–5 × 108 IU) are introduced surgically into the pancreas of KrasG12DFSF/+-Tp53Frt/Frt-R26CreERT2/+ mice to generate the R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1 model. 7 days after surgery, mice were treated with caerulein. The tissue specificity is provided by the human Krt19 promoter, which drives the expression of the Flpo recombinase, resulting in the activation of the latent mutant KrasG12DFSF/+ and the inactivation of the conditional Tp53Frt allele along with the constitutive expression of an shRNA under the U6 promoter. The time-restricted restoration of the gene of interest is mediated by the R26CreERT2 ubiquitous CreERT2 strain upon tamoxifen treatment and removal of the cassette containing the shRNA flanked by LoxP sites. n, Left, T2-weighted MRI scans of tumour-bearing mice 19 weeks after orthotopic injection with the pLSM2 lentiviral system carrying two shRNAs specific for murine Smarcb1. The tumours extensively invade the abdominal cavity. Right, immuno-phenotype of a tumour induced with pLSM2-shSmarcb1. Poorly cohesive, undifferentiated tumour cells express the pancreatic-specific markers Pdx1 and Sox9, suggestive of a pancreatic epithelial cell of origin. o, Kaplan–Meier analysis of tumour incidence in R26CreERT2/+-KPFrt/Frt mice challenged with orthotopic injections of the pLSM2-shSmarcb1 and pLSM2-shCtrl constructs. Knockdown of Smarcb1 in the mosaic model system results in higher penetrance and shorter latency (R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1, n = 53; R26CreERT2/+-KPFrt/Frt-pLSM2-shCtrl, n = 39). p, Quantification of the metastatic burden in R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1 mice versus R26CreERT2/+-KPFrt/Frt-pLSM2-shCtrl mice, assessed by counting the combined number of liver, lung and peritoneal metastases (R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1, n = 23; R26CreERT2/+-KPFrt/Frt-pLSM2-shCtrl, n = 5). Data are mean ± s.d. of biological replicates. q, PCR from recombined and un-recombined genomic DNA isolated from vehicle- and tamoxifen-treated tumour-bearing mice. Genomic DNA was extracted 5 and 10 days after treatment in vivo. r, Kaplan–Meier survival analysis of R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1 tumours transplanted orthotopically in syngeneic C57BL/6 recipient mice (n = 5 per vehicle and d18 groups, n = 7 per d1 group). Early tamoxifen treatment and Smarcb1 restoration resulted in a significant and durable improvement in survival. s, Metastatic burden was estimated by counting the number of liver, peritoneal and lung metastasis in the experimental cohorts described in r (n = 5 per vehicle and Txd18 groups, n = 7 per Txd1 group). The early restoration of Smarcb1 greatly reduced the number of metastatic foci, suggesting that its deficiency is a requirement in tumour dissemination. Data are mean ± s.d. of biological replicates. NS, not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, by Mantel–Cox log-rank test (c, k, o, r), two-tailed chi-squared test (h) or unpaired two-tailed t-test (i, j, p, s). Scale bars, 100 μm (b, d, f, n). For gel source data, see Supplementary Figures.

Source data

Extended Data Figure 5 Transcriptomic and proteomic profiles of mesenchymal tumours.

a, The robust-multi-array-average-normalized probe signal levels from microarray data for each gene previously identified as pancreatic cancer classifiers14. Smarcb1-ablated tumours and mesenchymal clones display enrichment for the QM-PDA gene signature. b, Acute restoration of Smarcb1 in pancreatic tumours generated in R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1 mice results in the dysregulation of Myc transcriptomic targets and genes involved in global protein metabolism and global response to stress. Heat maps show the enrichment for specific gene ontology pathways in vehicle-treated tumours when compared with tamoxifen-treated, Smarcb1-restored tumours. Lesions were collected 10 days after treatment. c, Myc transcriptomic targets and genes involved in global protein metabolism and response to stress are enriched in MS-L escaper clones. d, Quantification of protein biosynthesis by OPP-incorporation analysis using FACS. Representative plots from Smarcb1-ablated and restored cultures established from GEMM-derived tumours. Cycloheximide (Chx)-treated cultures were used as negative controls. e, Western blot analysis for SMARCB1, Myc and ER-stress-response pathway proteins from independent tumours upon tamoxifen-mediated Smarcb1 restoration compared to vehicle controls and tumours generated from EPI and MS-L escapers. Vinculin was used as loading control. Tumours generated with the somatic technology were harvested 10 days after tamoxifen or vehicle treatment. Robust activation of the IRE1-α/MKK4 and IRE1-α/XBP-1 pathways is readily apparent. f, GSEA scores for the Atf2 signature in Smarcb1-ablated/deficient models. Left, vehicle versus tamoxifen-treated R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1-855 tumour-bearing mice; right, Atf2 gene-signature enrichment in MS-L escapers as compared to EPI. g, Immunohistochemical analysis of protein expression for SMARCB1, phospho-ATF2, and JUN in surgically resected human PDAC samples with high and low levels of SMARCB1. Images are of representative sections; scale bars, 100 μm. h, Kaplan–Meier analysis of survival in patients with surgically resected PDAC with available follow-up data segregated according to the expression levels of phospho-ATF2 (phospho-ATF2 score, 2–3+, n = 55; phospho-ATF2 score, 0–1, n = 79). Activation of the stress-response factor ATF2 results in reduced post-operative survival. P < 0.0001 by Mantel–Cox log-rank test. i, Bar plots for the relative abundance of phospho-ATF2 immuno-staining in SMARCB1-deficient and SMARCB1-proficient human pancreatic cancer. An inverse correlation in the expression levels of SMARCB1 and phospho-ATF2 in human PDAC is apparent (SMARCB1+ n = 138, SMARCB1− n = 16). P < 0.0001 by two-tailed Fisher’s exact test. For gel source data, see Supplementary Figures.

Extended Data Figure 6 The proto oncogene Myc is a master regulator in the Smarcb1 transcriptomic network.

a, Schematic model of Myc-rescue experiments. Short-term cultures from R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1-855 tumours were transduced with a Myc-expressing lentiviral vector and briefly selected. A LacZ expression vector was used as negative control. Cells were injected orthotopically into syngeneic mice assigned to either tamoxifen or vehicle treatment. b, Kaplan–Meier analysis of survival in mice transplanted with R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1-855 tumours rescued with Myc or LacZ and assigned to vehicle or tamoxifen treatment (n = 5 per group). c, Quantification of nestin+ areas in LacZ-control and Myc-reprogrammed R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1-855 tumours (n = 12 per group). Enforced expression of Myc resulted in a marked increase in the number of nestin+ cells per section and in the maintenance of a mesenchymal state. Data are mean ± s.d. of biological replicates. d, Representative haematoxylin and eosin (left) and nestin staining (right) of R26CreERT2/+-KPFrt/Frt-pLSM2-shSmarcb1-855 tumours rescued with Myc or LacZ. Myc overexpression keeps the cells in a mesenchymal state upon tamoxifen treatment. e, Myc overexpression rescues the steady-state levels of protein biosynthesis in Smarcb1-restored cells assessed by OPP incorporation and FACS analysis from freshly isolated tumour cells. f, Representative haematoxylin and eosin (left) and nestin staining (right) from EPI cells transduced with Myc or LacZ. Myc overexpression fully reprograms EPI clones, generating anaplastic, mesenchymal tumours. g, Kaplan–Meier analysis of survival in mice transplanted with EPI cells transduced with Myc or LacZ. MS-L cells were used as positive controls (n = 5 per group). Myc transduced EPI transplants faithfully recapitulate the aggressive behaviour of MS-L tumours. h, Functional rescues studies using a Myc- or LacZ-expressing vector. Western blot analysis showing that the sustained overexpression of Myc in Smarcb1 restored cells and in EPI clones engages the Jnk/Atf2 stress response pathway. Vinculin was used as loading control. i, Representative TEM sections from Smarcb1-proficient and Smarcb1-deficient tumours generated with the somatic conditional model and the stochastic model and rescued with Myc and LacZ, respectively. The sustained overexpression of Myc fully rescues the ultra-structural findings observed in the Smarcb1-deficient settings. Arrow indicates cytoplasmic fibres. NS, not significant; **P < 0.01, ****P < 0.001, by Mantel–Cox log-rank test (b, g) or unpaired two-tailed t-test (c). Scale bars, 100 μm (d, f); 4 μm (i, ×5,000); 500 nm (i, ×25,000). For gel source data, see Supplementary Figures.

Source data

Extended Data Figure 7 Genetic extinction of the ER-stress response pathway is lethal in Smarcb1-deficient PDAC.

a, Orthotopic primary tumours harbouring latent Flpo/Frt-dependent, tamoxifen-inducible shRNAs against Ern1 (shown as Ire1-α) were generated into the KPS∆/∆ background (R26Cag-FlpoERT2/+-KPS∆/∆p-LSM5-shIre1-α or R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl). Mice with palpable masses were assigned to tamoxifen or vehicle treatment. b, Western blot analysis of short-term cultures established from the model described above. 4-Hydroxytamoxifen treatment results in the robust knockdown of Ern1. Lysates were harvested 96 h after 4-hydroxytamoxifen treatment. Vinculin was used as loading control. c, Spherogenic assay after acute RNAi-mediated depletion of Ern1 achieved by 4-hydroxytamoxifen treatment (n = 3 per group). Impairment of clonal growth is observed in 4-hydroxytamoxifen-treated, Ern1-depleted spheroids as compared to vehicle-treated cells and shCtrl. Data are mean ± s.d. of technical replicates (one representative experiment out of three). d, Kaplan–Meier survival analysis of R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shIre1-α and R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl GEMMs after tamoxifen treatment. Continuous line, tamoxifen-treated mice; interrupted line, vehicle-treated mice (shErn1 and vehicle, n = 7; shErn1 and tamoxifen, n = 12; shCtrl and vehicle, n = 8; shCtrl and tamoxifen, n = 8). Ern1 extinction results in a robust improvement in overall survival. e, Western blot analysis showing that the RNAi-mediated ablation of Ern1 in a Smarcb1-deficient background and in Myc-reprogrammed EPI cells results in a marked decrease in the activity of Mkk4 kinase and its downstream effectors. Vinculin was used as loading control. Ern1 has an essential role in the engagement of the stress response pathway. Tunicamycin-treated EPI cells were used as positive control. f, Spherogenic assay for EPI, MS-L escapers and EPI-Myc escapers upon RNAi-mediated genetic depletion of Ern1 (n = 3 per group). Data are mean ± s.d. of technical replicates (one representative experiment out of three). g, Kaplan–Meier analysis of survival of NCr Nude mice orthotopically injected with EPI, MS-L and Myc-reprogrammed EPI cells expressing a lentiviral-based shErn1. Knockdown of Ern1 is lethal in MS-L- and Myc-EPI-derived tumours but shows no effect in EPI tumours transduced with LacZ (n = 5 per group). h, Histological analysis of primary pancreatic tumours from the R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shIre1-α GEMM treated with tamoxifen or vehicle. Depletion of Ern1 in Smarcb1-deficient tumours results in a profound apoptotic response (assessed by staining for cleaved caspase-3 (CC3)) and in residual epithelial remnants. Engagement of the JNK/p38 pathway in vivo was assessed by phospho-Atf2 staining. i, Histological analysis of pancreatic tumours resulting from orthotopic transplants of MS-L or EPI-Myc cells transduced with shErn1 or shCtrl vectors. Depletion of Ern1 in MS-L and Myc-EPI tumours results in a profound apoptotic response (assessed by staining for CC3) and in residual epithelial remnants. NS, not significant; **P < 0.01, ****P < 0.0001, by Mantel–Cox log-rank test (d, g). Scale bars, 100 μm (h, i). For gel source data, see Supplementary Figures.

Source data

Extended Data Figure 8 Genetic extinction of the JNK/p38 stress response pathway is lethal in a Smarcb1-deficient context.

a, Orthotopic tumours harbouring latent Flpo/Frt-dependent, tamoxifen-inducible shRNAs against Mkk4, Atf2 and Jun were generated in the KPS∆/∆ mouse background (R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shMkk4, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shAtf2, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shJun, and R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl). Tumour-bearing mice were assigned to tamoxifen or vehicle treatment. b, Western blot analysis for MKK4 levels in ex vivo cultures generated from R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shMkk4 tumours. Protein lysates were isolated 96 h after vehicle or 4-hydroxytamoxifen treatment. Vinculin was used as loading control. c, Histological analysis of primary tumours from the R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shMkk4 backgrounds treated with vehicle or tamoxifen and collected after 10 or 15 days of treatment. Engagement of the Jnk/p38/Atf2 pathway and apoptosis were assessed by phospho-Atf2 and cleaved caspase 3 (CC3) staining, respectively. d, Spherogenic assays for short-term spheroid cultures generated from the R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shMkk4, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shAtf2, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shJun, and R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl tumours (n = 3 per group). Treatment with 4-hydroxytamoxifen results in the impairment of 3D growth. Data are mean ± s.d. of technical replicates (one representative experiment out of three). e, Knockdown efficiency of Atf2 and Jun in tumour lysates collected after 10 days from tamoxifen treatment, as assessed by western blot. Vinculin and actin B were used as loading controls for Atf2 and Jun, respectively. f, g, Kaplan–Meier survival analysis of primary tumours (f) and orthotopic transplants (g) from R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shAtf2, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shJun, andR26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl GEMMs. Continuous line, tamoxifen-treated mice; interrupted line, vehicle-treated mice (n = 8 per group). h, Histological analysis of primary tumours from the R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shAtf2, R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shJun, and R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shCtrl tumour-bearing mice treated with vehicle or tamoxifen and collected at the beginning of the treatment, or after 10 or 15 days of treatment. i, Immunohistochemical analysis for Atf2, Jun and CC3 in sections obtained from R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shAtf2 and R26Cag-FlpoERT2/+-KPS∆/∆-pLSM5-shJun tumour-bearing mice assigned to vehicle or tamoxifen treatment. Apoptosis was assessed by CC3 staining. Tumours were collected 10 days after the beginning of the treatment. j, k, Spherogenic assays for MS-L and EPI spheroids transduced with lentiviral shRNA specific for Mkk4, Jun or Atf2 (n = 3 per group). Knock-down of Mkk4, Jun or Atf2 impairs the growth potential in vitro of MS-L cells with minimal effects on EPI cells. Data are mean ± s.d. of technical replicates (one representative experiment out of three for both groups). l, m, Kaplan–Meier survival analysis of NCr Nude mice orthotopically transplanted with EPI and MS-L cells transduced with lentiviral shRNA specific for murine Mkk4, Atf2 and Jun. shCtrl vector transduced cells were used as negative control (n = 5 per group). NS, not significant; *P < 0.05, **P < 0.01, ****P < 0.0001, by Mantel–Cox log-rank test (f, g, l, m). Scale bars, 100 μm (c, h, i). For gel source data, see Supplementary Figures.

Source data

Extended Data Figure 9 Genetic ablation of Mkk4 kinase delays tumour growth in the KP∆/∆ background.

a, Orthotopic tumours harbouring latent Flpo/Frt-dependent, tamoxifen-inducible shRNAs against Mkk4 were generated in a Kras-mutant, Tp53-deficient, Smarcb1-intact background (KP∆/∆). Tumour-bearing mice were assigned to tamoxifen or vehicle treatment. b, Kaplan–Meier survival analysis of R26Cag-FlpoERT2/+-KP∆/∆-pLSM5-shMkk4 (n = 8 per group), and R26Cag-FlpoERT2/+-KP∆/∆-pLSM5-shCtrl (n = 5 per group) GEMMs. Continuous line, tamoxifen-treated mice; interrupted line, vehicle-treated mice. NS, not significant; ****P < 0.0001 by Mantel–Cox log-rank test. c, d, Histological analysis of primary tumours from the R26Cag-FlpoERT2/+-KP∆/∆-pLSM5-shMkk4 or control backgrounds treated with vehicle or tamoxifen and collected after 10 days of treatment. Apoptotic response was assessed by immunostaining for CC3. Scale bars, 100 μm.

Source data

Extended Data Figure 10 Pharmacological manipulation of proteostasis is lethal in a Smarcb1-deficient genetic context.

a, b, In vitro 3D growth assay for Smarcb1-proficient and Smarcb1-deficient murine PDAC lines (n = 3 per group). Pharmacological treatment with proteasome and HSP90 inhibitors results in the marked impairment of clonogenic growth in Smarcb1-deficient background with limited efficacy in Smarcb1-proficient models. Data are mean ± s.d. of technical replicates (one representative experiment out of three). c, Kaplan–Meier survival analysis of NCr Nude mice orthotopically transplanted with Smarcb1-deficient and Smarcb1-proficient cells and treated with the HSP90 inhibitor AUY922 or vehicle control (EPI, MS-L, KC, KPC∆/∆, KPSC∆/∆: n = 5 per group; KSC∆/∆: n = 7 per group). P values were calculated using the Mantel–Cox log-rank test. d, Representative panels of Smarcb1-proficient (EPI) and Smarcb1-deficient (MS-L, KSC∆/∆, KPSC∆/∆) tumour-bearing mice treated with AUY922 or vehicle control; tumours were collected after 10 days of treatment. Top, haematoxylin and eosin staining. Bottom, CC3 staining, showing that impairment of the unfolded-protein response results in the induction of apoptotic cell death. Arrows indicate protein aggregates. e, Kaplan–Meier survival analysis of tumour-bearing mice transplanted orthotopically with Smarcb1-deficient KPSC∆/∆ cells and assigned to one of four treatment arms: vehicle (n = 5); AUY922 (n = 5); BIRB796 and SP600125 (n = 5); or AUY922, BIRB796 and SP600125 (n = 10). **P < 0.01, ****P < 0.0001 by Mantel–Cox log-rank test. f, The apoptotic response associated with the treatments was assessed by CC3 staining. Stress-response engagement was assessed by phospho-Atf2 staining. g, Representative sections from orthotopic PDX transplants treated with gemcitabine, AUY922 or a combination of gemcitabine and AUY922. Apoptotic response was assessed by CC3 staining. Scale bars, 100 μm (d, f, g).

Source data

Supplementary information

Supplementary Information

This file contains the uncropped blots with size marker indications. (PDF 745 kb)

Supplementary Data

This file contains Supplementary Table 1, clinical-pathological data. (XLSX 30 kb)

PowerPoint slides

Source data

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genovese, G., Carugo, A., Tepper, J. et al. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542, 362–366 (2017). https://doi.org/10.1038/nature21064

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature21064

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer